Applications for this trial have now closed.


COVID-19 Vaccine Clinical Trial

A Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a Quadrivalent Hemagglutinin Nanoparticle Influenza and SARS-CoV-2 rS Nanoparticle Combination Vaccine with Matrix-M1™ Adjuvant in Healthy Participants ≥ 50 to ≤ 70 Years of Age

Thank you for your interest in the above study, which is studying a combination vaccine candidate for both COVID-19 and the seasonal influenza. The aim of this study is to evaluate the safety and immunogenicity of the vaccine, which is being developed to prevent both seasonal flu and COVID-19 and/or to help prevent serious illness if infection does occur.

To complete this study, we need volunteer participants. We are looking for volunteers who:

    • are aged 50 – 70
    • are in good health
    • do not have any chronic health illnesses such as diabetes and heart disease
    • do not have any autoimmune diseases (e.g.: Type 1 Diabetes, Graves’ disease, coeliac, psoriasis, rheumatoid arthritis etc)
    • have no history of cancer in last 3 years
    • have received both doses of an approved COVID-19 vaccine prior to July 30th 2021

Those who choose to volunteer and meet the eligibility criteria will participate in the study for around six months, visiting the Hunter Diabetes Centre (AIM Centre) 8 times during this period. Participants will receive financial reimbursement for travel costs incurred for each visit.

There will be no placebos given in this study, meaning all participants will receive the investigational vaccine, but in varying doses. Physical examinations, blood tests and electronic diaries will be used to track each participant’s safety and progress throughout the study.

Recruitment for this study will begin on September 10th and continue for 2-3 weeks. 

Please read the information form below, which details the trial and its requirements. Feel free to discuss it with your family, friends, and GP if you wish.


If you meet the above criteria, have read the information form, and are interested in knowing more, please complete the form below.

If you have any questions, please contact our team of Clinical Trial Coordinators at or phone (02) 4963 2323.


Applications for this trial have now closed.